Trials / Completed
CompletedNCT03589313
Pharmacokinetics of GLPG3067 in Male Subjects With Cystic Fibrosis.
Evaluation of the Pharmacokinetics, Safety and Tolerability of a Single Dose of GLPG3067 Administered as Solid Formulation in Male Subjects With Cystic Fibrosis.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Galapagos NV · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This clinical study is a Phase I, open-label, single-center study designed to evaluate the pharmacokinetics profile of a single oral dose of GLPG3067 in adult male subjects with cystic fibrosis in fed state.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GLPG3067 single dose | GLPG3067 film coated tablets provided at Day 1. |
Timeline
- Start date
- 2018-02-12
- Primary completion
- 2018-03-26
- Completion
- 2018-03-26
- First posted
- 2018-07-17
- Last updated
- 2018-07-17
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT03589313. Inclusion in this directory is not an endorsement.